- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04309084
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
A Phase I Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK 001) in Multiple Myeloma Patients Following Autologous Stem Cell Transplant in the Front-line Setting.
Study Overview
Status
Conditions
- Cardiovascular Diseases
- Vascular Diseases
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Multiple Myeloma
- Paraproteinemias
- Blood Protein Disorders
- Antineoplastic Agents
- Physiological Effects of Drugs
- Analgesics, Non-Narcotic
- Peripheral Nervous System Agents
- Hemostatic Disorder
- Analgesics
- Sensory System Agents
- Neoplasm, Plasma Cell
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Colorado Blood Cancer Institute
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University
-
-
New York
-
Buffalo, New York, United States, 14203
- Roswell Park Comprehensive Cancer Institute
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Subject Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
Subject has eligible disease status:
Newly diagnosed multiple myeloma undergoing or completed induction therapy prior to undergoing first ASCT and presenting MRD positive by NGS after completion of induction therapy.
- Subject is > 18 and ≤ 75 years of age at the time of signing the informed consent form (ICF).
- Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.
- Subject is willing and able to adhere to the study schedule and other protocol requirements.
- Performance status of Eastern Cooperative Oncology Group (ECOG) < 2
- Ability to be off immunosuppressive drugs for at least 3 days prior to the CYNK-001 cell infusion. Steroids at the equivalent of no more than 5 mg prednisone per day are permissible.
- Subjects must have autologous peripheral blood stem cell graft available in storage for additional transplant in the event of engraftment failure.
Female of childbearing potential (FCBP) must not be pregnant and agree to not becoming pregnant for at least 28 days following the CYNK-001. FCBP must agree to use an adequate method of contraception during the treatment period.
FCBP is a female who: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months).
- Male subjects must agree to use a condom during sexual contact for at least 28 days following the CYNK-001, even if he has undergone a successful vasectomy.
Subject Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
- Subject has plasma cell leukemia.
- Subject has non-secretory myeloma.
- Subject has previously undergone allogeneic stem cell transplant.
- Subject has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study.
- Subject has any condition including the presence of laboratory abnormalities which places the subject at unacceptable risk if he or she were to participate in the study.
- Subject has any condition that confounds the ability to interpret data from the study.
- Subject has a known sensitivity or allergy to lenalidomide which will limit the subject from receiving the mandatory lenalidomide maintenance as part of the study plan.
- Subject has aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase ≥ 2.5 x the upper limit of normal (ULN) within 7 days prior to melphalan administration. Transient abnormalities should be discussed with the medical monitor.
- This eligibility criterion removed with Amendment 1
- Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 at screening calculated using the Modification of Diet in Renal Disease Study equation. (Levey, 2006)
- Subject has a bilirubin level > 2 mg/dL (unless subject has known Gilbert's disease) at screening.
- Subject has had prior treatment with biologic antineoplastic agents less than 7 days before CYNK-001 infusion and at least 5 half-lives since (excludes melphalan). (Exception will be granted for monoclonal antibodies that are known to have long half-lives, in which case a minimum of 2 weeks from last dose will be required). For agents that have known AEs occurring beyond these specified days after administration, this period must be extended beyond the time during which acute AEs are known to occur. Treating physicians are encouraged to discuss cases with the Medical Monitor.
- Subject is pregnant or breastfeeding.
- Subject has new or progressive pulmonary infiltrates or pleural effusion large enough to be detected by chest x-ray or computerized tomography (CT) scan within 2 weeks of CYNK-001 infusion.
- Subject has active autoimmune disease other than controlled connective tissue disorder or those who are not on active therapy.
- Subject who is human immunodeficiency virus (HIV) positive is excluded due to increased risk of lethal infections when treated with myeloablative chemotherapy.
Subject has history of malignancy, other than MM, unless the subject has been free of disease for > 3 years from the date of signing the ICF. Exceptions include the following noninvasive malignancies:
- Basal cell carcinoma of the skin
- Squamous cell carcinoma of the skin CYNK-001
- Carcinoma in situ of the cervix
- Carcinoma in situ of the breast
- Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)
- Subject has a history of severe asthma and is presently on chronic medications or has a history of other symptomatic pulmonary disease.
- Untreated chronic infection or treatment of any infection with systemic antibiotics within 2 weeks prior to melphalan.
- Subject has any other organ dysfunction (Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Grade 3 or greater) that will interfere with the administration of the therapy according to this protocol.
- Subject has a resting left ventricular ejection fraction (LVEF) of < 35% obtained by echocardiography or multigated acquisition scan (MUGA).
- Subject was treated with an investigational product no less than 28 days before CYNK-001 infusion. Subject must no longer be a participant in the previous interventional study at the time of the CYNK-001 infusion. (Subjects who are under survival follow-up or observation associated with a study are permitted, and if treatment information is collected for this period, "Investigational Study" must be used for capturing the study treatment.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Phase I
Up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT.
Once MTD has been determined, the Expansion cohort will commence.
|
CYNK-001 is an allogeneic off the shelf cell therapy enriched for CD56+/CD3- NK cells expanded from human placental CD34+ cells.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dose-Limiting Toxicity (DLT)
Time Frame: Up to 28 days
|
Safety Assessment of Dose-Limiting Toxicity (DLT)
|
Up to 28 days
|
Maximum Tolerated Dose (MTD) or Maximum Planned Dose (MPD)
Time Frame: Up to 28 days
|
Safety Assessment of MTD OR MPD
|
Up to 28 days
|
Adverse Events (AE)
Time Frame: Up to 12 months
|
Safety Assessment of AE's
|
Up to 12 months
|
Rate of Minimal Residual Disease (MRD) Negativity
Time Frame: Day 90-100
|
Efficacy Assessment of MRD
|
Day 90-100
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Minimal Residual Disease (MRD) Response
Time Frame: Day 90-100
|
Efficacy Assessment of MRD
|
Day 90-100
|
Time to MRD Response
Time Frame: up to 12 months
|
Efficacy Assessment of MRD
|
up to 12 months
|
International Myeloma Working Group (IMWG) response
Time Frame: up to 12 months
|
Efficacy Assessment of response
|
up to 12 months
|
duration of clinical response
Time Frame: up to 12 months
|
Efficacy Assessment of response
|
up to 12 months
|
Progression-free survival
Time Frame: up to 12 months
|
Efficacy Assessment of response
|
up to 12 months
|
time to progression
Time Frame: up to 12 months
|
Efficacy Assessment of response
|
up to 12 months
|
overall survival
Time Frame: up to 12 months
|
Efficacy Assessment of response
|
up to 12 months
|
Quality of life questionnaire
Time Frame: up to 12 months
|
Efficacy Assessment of response
|
up to 12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Lymphatic Diseases
- Neoplasms
- Cardiovascular Diseases
- Hemostatic Disorders
- Blood Coagulation Disorders
- Disease
- Vascular Diseases
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Hematologic Diseases
- Hemorrhagic Disorders
- Immune System Diseases
- Lymphoproliferative Disorders
- Neoplasms by Histologic Type
- Paraproteinemias
- Immunoproliferative Disorders
- Blood Protein Disorders
Other Study ID Numbers
- CYNK-001-MM-002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on CYNK-001
-
Celularity IncorporatedLung Biotechnology PBC; California Institute for Regenerative Medicine (CIRM); ID...Active, not recruitingCoronaviridae Infections | Nidovirales Infections | RNA Virus Infections | Respiratory Tract Infections | Coronavirus Infection | Pneumonia, Viral | Pneumonia | Lung Diseases | ARDS | Coronavirus | Severe Acute Respiratory Syndrome Coronavirus 2 | Respiratory Tract Disease | Virus Disease | Physiological Effects of... and other conditionsUnited States
-
Celularity IncorporatedTerminatedGlioblastoma Multiforme | Molecular Mechanisms of Pharmacological Action | Giant Cell Glioblastoma | Astrocytoma, Grade IV | Physiological Effects of Drugs | Peripheral Nervous System Agents | Analgesics | Analgesics, Non-narcotic | Cyclophosphamide | Immunosuppressive Agents | Immunologic Factors | Antiviral... and other conditionsUnited States
-
Celularity IncorporatedRecruitingNeoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Hematologic Neoplasms | Physiological Effects of Drugs | Peripheral Nervous System Agents | Analgesics | Analgesics, Non-narcotic | Antimetabolites, Antineoplastic | Leukemia in Remission | Relapsed... and other conditionsUnited States
-
Celularity IncorporatedWithdrawnGlioblastoma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Astrocytoma, Grade IVUnited States
-
Toll Biotech Co. Ltd. (Beijing)Recruiting
-
Patagonia Pharmaceuticals, LLCCompletedCongenital IchthyosisUnited States
-
IntegoGen, LLCWithdrawnHidradenitis SuppurativaUnited States
-
Frontera TherapeuticsRecruitingBiallelic RPE65 Mutation-associated Retinal DystrophyChina
-
Longbio PharmaActive, not recruitingMyelodysplastic Syndrome (MDS)China
-
Astrogen, Inc.RecruitingAutism Spectrum DisorderKorea, Republic of